Refine
Year of publication
Document Type
- Article (838)
- Preprint (777)
- Conference Proceeding (7)
- Part of Periodical (4)
- Working Paper (3)
- Book (2)
- Course Material (1)
Has Fulltext
- yes (1632)
Is part of the Bibliography
- no (1632)
Keywords
- Heavy Ion Experiments (21)
- breast cancer (13)
- Hadron-Hadron scattering (experiments) (12)
- Mammakarzinom (12)
- glioblastoma (12)
- Hadron-Hadron Scattering (11)
- LHC (9)
- Behandlung (8)
- Metastasen (8)
- CDK4/6 (6)
- Heavy-ion collision (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- schizophrenia (6)
- treatment (6)
- Heavy-ion collisions (5)
- MRI (5)
- metastases (5)
- risk (5)
- ALICE experiment (4)
- Collective Flow (4)
- Glioblastoma (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- Risiko (4)
- glioma (4)
- hypoxia (4)
- immunotherapy (4)
- trials (4)
- ALICE (3)
- Breast cancer (3)
- Diffraction (3)
- EGFR (3)
- Elastic scattering (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- PDGFRβ (3)
- Relativistic heavy-ion collisions (3)
- bevacizumab (3)
- biomarker (3)
- chemotherapy (3)
- chimeric antigen receptor (3)
- cirrhosis (3)
- cytokine-induced killer cells (3)
- global change (3)
- meningioma (3)
- metastatic (3)
- neoadjuvant therapy (3)
- pp collisions (3)
- stroke (3)
- targeted therapy (3)
- Alpelisib (2)
- Atezolizumab (2)
- Beam Energy Scan (2)
- Beauty production (2)
- CIK cells (2)
- COPD (2)
- COVID-19 (2)
- CRM (2)
- Charm physics (2)
- Chiral Magnetic Effect (2)
- Collectivity (2)
- Correlation (2)
- Critical care (2)
- Diagnostik (2)
- Drug therapy (2)
- Elliptic flow (2)
- Epilepsy (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Extended donor criteria (2)
- Fasting (2)
- Früherkennung (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- Genetics (2)
- Genetics research (2)
- Glucose (2)
- HER2/neu (2)
- IDH mutation (2)
- Immunology (2)
- KGF (2)
- Katherine (2)
- Ketogenic diet (2)
- Leptin (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Lokalrezidiv (2)
- MEG (2)
- MRT (2)
- Machine learning (2)
- Malaria (2)
- Mamma (2)
- NK-92 (2)
- Nachsorge (2)
- PARP (2)
- PD-1 (2)
- PD-L1 (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Peritonitis (2)
- Personalized medicine (2)
- Polarization (2)
- Predictive markers (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Psychiatric disorders (2)
- Pulmonary embolism (2)
- QCD (2)
- Quarkonium (2)
- RHIC (2)
- ROS (2)
- Radiation (2)
- Radiotherapy (2)
- Richtlinie (2)
- STAR (2)
- Sestrin 2 (2)
- Shear viscosity (2)
- Single electrons (2)
- Supportivtherapie (2)
- Surgery (2)
- Targeted therapy (2)
- Temozolomide (2)
- Tomosynthese (2)
- T‑DM1 (2)
- Ultraschall (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- adult (2)
- advanced (2)
- allogeneic stem cell transplantation (2)
- alpelisib (2)
- anaemia (2)
- anti-angiogenic therapy (2)
- atezolizumab (2)
- biodiversity protection (2)
- brain metastases (2)
- brain metastasis (2)
- breast (2)
- composite structures (2)
- conservation funding (2)
- conservation planning (2)
- decision making (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- galactography (2)
- galactomosynthesis (2)
- genome (2)
- guideline (2)
- local recurrence (2)
- mTOR (2)
- mitochondria (2)
- neoadjuvante Therapie (2)
- neural oscillations (2)
- post-2020 biodiversity targets (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- starvation (2)
- strategic site selection (2)
- studies (2)
- supportive therapy (2)
- tomosynthesis (2)
- treatment/therapy (2)
- tumor microenvironment (2)
- ultrasound (2)
- 140Ce (1)
- 19F MR spectroscopy (1)
- 1H MR spectroscopy (1)
- 2-deoxyglucose (2-DG) (1)
- 2-hydroxyglutarate (1)
- 4-1BB (1)
- 900 GeV (1)
- AB-serum (1)
- ABC transporters (1)
- ALICE detector (1)
- AML (1)
- APP processing (1)
- APRI (1)
- ARDS (1)
- ATPases (1)
- Active middle ear implants (1)
- Acute cough (1)
- Acute myeloid leukemia (1)
- Addison’s disease (1)
- Advanced biliary tract cancer (1)
- Advanced breast cancer (1)
- Adverse events (1)
- Aiolochroia crassa (1)
- Alien (1)
- All-trans retinoic acid (1)
- Allogeneic hematopoietic stem (1)
- Alzheimer (1)
- Ambroxol (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Angiogenesis (1)
- Anti-nuclei (1)
- Antihormone therapy (1)
- Appendectomy (1)
- Appendicitis (1)
- Artemether-lumefantrine (1)
- Artemisinin-combination-therapy (1)
- Artenschutz (1)
- Artesunate (1)
- Artificial Intelligence (1)
- Asset Purchase Programme (1)
- Astrocytoma (1)
- Auditory system (1)
- B cell malignancies (1)
- B-slope (1)
- BEACOPP (1)
- BRAF (1)
- BRAF V600E (1)
- BTC (1)
- Baryonic resonances (1)
- Beam energy scan (1)
- Bevacizumab (1)
- Big Data (1)
- Biodiversity (1)
- Biodiversity Data (1)
- Biodiversität (1)
- Biogeographical representativeness (1)
- Bioinformatics (1)
- Biological (1)
- Biomarker (1)
- Biomarkers (1)
- Biomonitoring (1)
- Biotopschutz (1)
- Bipolar disorder (1)
- Blood-brain barrier (1)
- Bone conduction devices (1)
- Bone metastases (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brain metastasis (1)
- Brain tumor (1)
- Burkholderia arboris (1)
- Business strategy in drug development (1)
- C5 acylcarnitine (1)
- CAR (1)
- CD137 (1)
- CD3/CD19 depletion (1)
- CD74 (1)
- CDI (1)
- CDK4/CDK6 (1)
- COVID (1)
- CTLA-4 (1)
- CVD biomarker (1)
- CVID (1)
- CYP450 (1)
- Cancer (1)
- Cancer genomics (1)
- Candida (1)
- Canonical suppression (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Cell biology (1)
- Cell membranes (1)
- Central Bank Communication (1)
- Central nervous system metastases (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Cherenkov counter: lead-glass (1)
- Chimerism (1)
- Chiral magnetic effect (1)
- Circadian (1)
- Cleanliness level (1)
- Clinical genetics (1)
- Clinical study (1)
- Closure (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Comorbidities (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Complicated appendicitis (1)
- Consensus statement (1)
- Conservation (1)
- Coronary heart disease (1)
- Covid19-nmr (1)
- Critical point (1)
- Cytoskeleton (1)
- DDIT4 (1)
- DEE (1)
- DNA methylation (1)
- DST (1)
- Data management (1)
- Data sharing (1)
- Decision trees (1)
- Depression (1)
- Deuteron production (1)
- Dexamethasone (1)
- Di-hadron correlations (1)
- Diagnostic differentiation (1)
- Diagnostic markers (1)
- Diesel (1)
- Digitization (1)
- Direct oral anticoagulation (1)
- Drug susceptibility testing (1)
- Drug targeting (1)
- E/I-Balance (1)
- EBV (1)
- EET (1)
- EGFR inhibitor (1)
- EGFRvIII mutation (1)
- EMT (1)
- ERBB2 (1)
- ERBB2 (HER2/neu) (1)
- Ecosystem integrity (1)
- Ecosystems (1)
- Edema (1)
- Edition (1)
- Electromagnetic transitions (1)
- Electron-pion identification (1)
- Electronic properties and materials (1)
- Electrophysiology (1)
- Electroweak interaction (1)
- Emotions (1)
- Endothelial permeability (1)
- Entomology (1)
- Environment (1)
- Epidemiology (1)
- Epidermal growth factor receptor (1)
- Epstein-Barr virus (1)
- Essential biodiversity variables (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Ewing sarcoma (1)
- Exosomes (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extracellular RNA (eRNA) (1)
- FFPE (1)
- FIB-4 (1)
- Falciparum (1)
- Fc receptor (1)
- Femtoscopy (1)
- Ferroelectrics and multiferroics (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Filgrastim (1)
- First site of metastatic disease (1)
- Fistula (1)
- Flow (1)
- Forward Guidance (1)
- Forward physics (1)
- Frankfurt am Main (1)
- Freezeout (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Gamma-Band Activity (1)
- Gene regulation (1)
- German PID-NET registry (1)
- Glioblastoma survival (1)
- Glioma (1)
- Grading (1)
- Graft function (1)
- Graft survival (1)
- Groomed jet radius (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- Guided waves (1)
- Guidelines (1)
- HADES (1)
- HBT (1)
- HBV (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HIPPO signalling (1)
- HLA class II (1)
- HLA peptidome (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronization (1)
- Hand-foot syndrome (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health policy (1)
- Healthy stem cell donors (1)
- Heart regeneration (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion collisions (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Heavy-ion reactions (1)
- Hepatitis C virus (1)
- Herbaria (1)
- Heregulin (1)
- Hif-1 alpha (1)
- Hif1α (1)
- Higher moments (1)
- Hippocampus (1)
- Human behaviour (1)
- Hyperons (1)
- IDH1 inhibitor (1)
- IL-15 (1)
- IL-21 (1)
- IVA interference tandem mass spectrometry (1)
- IgG substitution therapy (1)
- IgGAM (1)
- Immunogenetics (1)
- Immunomodulatory agents (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Induced pluripotent stem cells (1)
- Induction chemotherapy (1)
- Influenza (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Intra-abdominal infection (1)
- Invariant Mass Distribution (1)
- Inverse kinematics (1)
- Ionisation energy loss (1)
- Ischemia–reperfusion injury (1)
- Isoflurane (1)
- Isoscalar giant resonances (1)
- Isoxazoline Alkaloids (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KCGS (1)
- KPS (1)
- Kreuzenzian (1)
- Kreuzenzian-Ameisenbläuling (1)
- LC3B (1)
- LTER (1)
- Laparoscopic appendectomy (1)
- Laparostomy (1)
- Laubmoss (1)
- Lebermoos (1)
- Lesion (1)
- Library screening (1)
- Lipid metabolism (1)
- Liver transplantation (1)
- London (1)
- Long term output (1)
- Long-term ecological monitoring (1)
- Long‐term ecosystem research (1)
- Low grade glioma (1)
- Low volume prep (1)
- Low-molecular-weight heparin (1)
- Luciferase (1)
- Lung cancer (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MACS (1)
- MET (1)
- MGMT (1)
- MGMT promoter (1)
- MM-121 (1)
- MRI patterns of gliomas (1)
- Magnetic properties and materials (1)
- Magnetic resonance imaging (MRI) (1)
- Malariae (1)
- Malignant meningioma (1)
- Mammalian target of rapamycin (1)
- Marginal grafts (1)
- Material budget (1)
- Materials science (1)
- Medical imaging (1)
- Meningioma (1)
- Mental health and psychiatry (1)
- Mesh (1)
- Meta-analysis (1)
- Metabolism (1)
- Metastatic (1)
- MicroRNAs (1)
- MicroRNAs (miRNAs) (1)
- Mid-rapidity (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Mitochondria (1)
- Mixed hearing loss (1)
- Models & methods for nuclear reactions (1)
- Molecular biology (1)
- Molecular matched therapy (1)
- Molecular neuroscience (1)
- Molecular profiling (1)
- Molecular subtypes (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiomics (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- N-methyl-D-aspartate receptor (1)
- NADPH oxidase (1)
- NK cells (1)
- NMR spectroscopy (1)
- NSAIDs (1)
- NSCLC (1)
- NTM (1)
- Nanoscale materials (1)
- Neoadjuvant therapy (1)
- Neolithic (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Network analysis (1)
- Neural network (1)
- Neuropilin (1)
- Neuroscience (1)
- Neutron physics (1)
- Nimotuzumab (1)
- Non-falciparum (1)
- Non-interventional study (1)
- Non-trauma (1)
- Non-tuberculous mycobacteria (1)
- Nonflow (1)
- Noninferiority (1)
- Nox1 (1)
- NoxO1 (1)
- Nuclear Physics (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nucleophosmin-1 (1)
- Nucleus (1)
- Nutrition (1)
- Obesity (1)
- Observation (1)
- Oligodendroglioma (1)
- Omics (1)
- Oncology (1)
- Open abdomen (1)
- Organ allocation (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoporosis (1)
- Outcome (1)
- Ovale (1)
- PID prevalence (1)
- PML (1)
- PTEN (1)
- PXA (1)
- PYTHIA (1)
- Paediatrics (1)
- Pancreas transplantation (1)
- Pancreatitis (1)
- Parainfluenza (1)
- Particle and Resonance Production (1)
- Particle production (1)
- Pathological complete response (1)
- Pathology (1)
- Patterns of care (1)
- Pb–Pb (1)
- Pentaglobin (1)
- Pharmacy setting (1)
- Phase transitions and critical phenomena (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Phylogenomics (1)
- Physical and mental health (1)
- Physiology (1)
- PillCamColon2 (1)
- Plasmodium (1)
- Pneumonia (1)
- Polyps (1)
- Population genetics (1)
- Pre-emptive immunotherapy (1)
- Predictive medicine (1)
- Production Cross Section (1)
- Prognostic models (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Proton (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Pseudomonas aeruginosa (1)
- Psychiatry (1)
- Psychometrics (1)
- Pulmonary edema (1)
- Pyogenic spondylodiscitis (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quark–gluon plasma (1)
- Questionnaires (1)
- Quinine (1)
- RMS (1)
- RNA (1)
- RNA PT (1)
- RNA modification (1)
- Radiation necrosis (1)
- Radiative capture (1)
- Rapidity Range (1)
- Re-exploration (1)
- Reactive oxygen species (1)
- Red blood cell transfusion (1)
- Regression analysis (1)
- Rehabilitation (1)
- Reigen (1)
- Reintervention (1)
- Rejection (1)
- Relativistic heavy ion physics (1)
- Remote ischemic conditioning (1)
- Renal lesions (1)
- Research Article (1)
- Research Infrastructure (1)
- Research infrastructure (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- Resonances (1)
- Respiratory distress syndrome (1)
- Respiratory syncytial virus (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- Risk factor (1)
- SARS-CoV-2 (1)
- SF-12 (1)
- SKALE score (1)
- SNP (1)
- STAMPE2 (1)
- SWATH (1)
- Salivary gland carcinoma (1)
- Schizophrenia (1)
- Schnitzler, Arthur (1)
- Seasonal variation (1)
- Semantics (1)
- Sepsis (1)
- Seribantumab (1)
- Severe bacterial infection (1)
- Severe malaria (1)
- Side effect (1)
- Single muons (1)
- Site networks (1)
- Small molecules (1)
- Socio-ecology (1)
- SoftDrop (1)
- Solar insolation (1)
- Sorafenib (1)
- Sozialpsychiatrischer Dienst (1)
- Spin alignment (1)
- Splitting function (1)
- Sponges (1)
- Stadtentwicklung (1)
- Stadtökonomie (1)
- Status epilepticus (1)
- Stem-cell therapies (1)
- Stentoplasty (1)
- Storage ring (1)
- Strangeness (1)
- Strangeness enhancement (1)
- Structure Elucidation (1)
- Suicide (1)
- Sunlight (1)
- Superinfection (1)
- Superoxide (1)
- Surgical oncology (1)
- Synaptic plasticity (1)
- Synthetic (1)
- Systematic Uncertainty (1)
- T-DM1 (1)
- TGF-β (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TIRADS (1)
- TOR signalling (1)
- TR (1)
- TRPA1 (1)
- TTW nodules (1)
- Tacrolimus (1)
- Tailored medicine (1)
- Taxonomy (1)
- Technical data (1)
- Technique (1)
- Tet-inducible system (1)
- Therapeutic anticoagulation (1)
- Therapies (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Timing (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Trauma (1)
- Treatment outcome (1)
- Trigger (1)
- Triple negative (1)
- Tumor heterogeneity (1)
- Tumor infiltrating lymphocytes (1)
- Uncomplicated appendicitis (1)
- Unconventional Monetary Policy (1)
- Upper respiratory tract infection (1)
- VEGF (1)
- VEGF receptors (1)
- VEGFR (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- Vascular emergencies (1)
- Vector Boson Production (1)
- Versorgungsstrukturen (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Vesicles (1)
- Viral load (1)
- Warburg effect (1)
- Weltstadt (1)
- WoMo score (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Zuckerkandl’s tubercle (1)
- Zwangseinweisungen (1)
- accident (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acute coronary syndromes (1)
- acute‐on‐chronic liver failure (1)
- adjuvant chemotherapy (1)
- adoptive cancer immunotherapy (1)
- adrenal insuffciency (1)
- advanced breast cancer (1)
- advanced melanoma (1)
- agaricomycetes (1)
- age (1)
- age-related macular degeneration (1)
- alirocumab (1)
- alleles (1)
- amphiregulin (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- angiogenesis (1)
- angiopoietin-2 (1)
- antibiotic (1)
- anticonvulsants (1)
- antifungal agents (1)
- antifungals (1)
- antihormone therapy (1)
- antiviral therapy (1)
- apoptosis (1)
- aridity (1)
- astrocytoma (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- autophagy (1)
- axions (1)
- biogeographic legaciese (1)
- biologicals (1)
- biomarkers (1)
- biosecurity (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- bronchial epithelium (1)
- burkholderia (1)
- burkholderia cepacia complex infections (1)
- c-kit (1)
- calorimeter: electromagnetic (1)
- cancer immunotherapy (1)
- capture (1)
- cell therapy (1)
- cell transplantation (1)
- cellular therapy (1)
- cerebral pseudoprogression (1)
- cerebral radiation necrosis (1)
- cerebrospinal fluid (1)
- cerium (1)
- cetuximab-bevacizumab therapy sequence (1)
- chemogenomic set (1)
- children and adolescents (1)
- chronic viral hepatitis (1)
- circulation (1)
- climate gradient (1)
- clinical trial (1)
- clonal transfer (1)
- co-infection (1)
- colon carcinoma (1)
- complementary psychosocial care (1)
- complete response (1)
- concept (1)
- conservation (1)
- continuum model (1)
- copy number polymorphism (1)
- cross-section (1)
- cryo-EM (1)
- cryopreservation (1)
- cystic fibrosis (1)
- cytotoxic T cells (1)
- dE/dx (1)
- dabrafenib (1)
- dark matter experiments (1)
- dental implants (1)
- detector (1)
- dexamethasone (1)
- diffusion-weighted magnetic resonance imaging (1)
- digestion artifact (1)
- discomfort/pain (1)
- discontinuation (1)
- disease outbreaks (1)
- disease prevalence (1)
- disease progression (1)
- domestication (1)
- doxycycline (1)
- drug discovery (1)
- druggable genome (1)
- early childhood (1)
- ectosomes (1)
- elderly (1)
- elderly patients (1)
- electronics: readout (1)
- electrophoresis (1)
- emergency care (1)
- endemisch (1)
- epidermal growth factor receptor (1)
- epilepsy (1)
- epiregulin (1)
- everolimus (1)
- evolution (1)
- ex vivo expansion (1)
- exosomes (1)
- exotic (1)
- experimental results (1)
- expertise (1)
- extracellular vesicles (1)
- familial amyloid nephropathy with urticaria and deafness (1)
- fibre: optical (1)
- fibrotest (1)
- focused electron beam induced deposition (1)
- forest classification (1)
- forest functional similarity (1)
- fragment screening (1)
- fresh frozen plasma (1)
- freshwater ecosystems (1)
- functional connectivity (1)
- fungal infection (1)
- galunisertib monohydrate (LY2157299) (1)
- gamma (1)
- gel (1)
- gene flow (1)
- genes (1)
- genetics (1)
- genotype (1)
- genotype determination (1)
- geriatric medicine (1)
- germ cell tumors (1)
- glioblastoma survival (1)
- glioma microenvironment (1)
- gliomas (1)
- gliomatosis cerebri growth pattern (1)
- glycolysis (1)
- guidelines (1)
- habitat destruction (1)
- heavy ion experiments (1)
- heavy-ion collisions (1)
- hemodynamic (1)
- hepatitis c (1)
- high-dose chemotherapy (1)
- histology (1)
- histopathological growth pattern (1)
- human (1)
- hydrocephalus (1)
- hyperalgesia (1)
- hypoxia-induced cell death (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitors (1)
- immune checkpoint inhibitors (ICI) (1)
- immune infiltration (1)
- immune related adverse events (irAE) (1)
- immune response (1)
- impact (1)
- inducible gene expression (1)
- infections (1)
- infiltration (1)
- inflammation (1)
- injury (1)
- insect abundance (1)
- inter-individual variability (1)
- interim positron emissiontomography (1)
- intraventricular chemotherapy (1)
- invasion (1)
- invasive growth (1)
- investigational (1)
- involuntary hospitalization (1)
- isocaloric ketogenic diet (1)
- isovaleric acidaemia (1)
- kidney function (1)
- kinase inhibitor (1)
- land use (1)
- lapatinib (1)
- leptomeningeal disease (1)
- leptomeningeal metastases (1)
- leukopenia (1)
- liver metastasis (1)
- lockdown (1)
- long-term protection (1)
- long-term research (1)
- long36 term protection (1)
- low-density lipoprotein cholesterol (1)
- lymphoma (1)
- mTOR inhibition (1)
- magentoencephalography (MEG) (1)
- magnetic resonance imaging (1)
- magnetoencephalography (1)
- major adverse cardiovascular events (1)
- malignant glioma (1)
- management (1)
- marked lymph node (1)
- mass spectrometry (1)
- medical device (1)
- medulloblastoma (1)
- melanoma (1)
- membrane proteins (1)
- mental health services (1)
- mentalizing (1)
- metabolic cancer therapy (1)
- metabolism (1)
- metastasis (1)
- metastatic renal cell carcinoma (1)
- microbial colonization (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- moisturing cream (1)
- molecular machines (1)
- mouthwash (1)
- mouthwash solution (1)
- multifocal (1)
- multiplexed immunofluorescence (1)
- murine model (1)
- n_TOF (1)
- native (1)
- natural killer cells (1)
- neoadjuvant chemoradiotherapy (1)
- neoadjuvant immunochemotherapy (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neuroimaging (1)
- neurological complication (1)
- neurological side effects (1)
- neutron (1)
- neutropenia (1)
- nitrogen (1)
- nivolumab (1)
- nociceptors (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- non-invasive fibrosis assessment (1)
- nonnative (1)
- nuclear receptor (1)
- nucleoside analysis (1)
- nucleosynthesis (1)
- nutrient availability (1)
- omega stringer (1)
- open guided waves (1)
- oral cavity cancer (1)
- oscillation (1)
- outbreak (1)
- ovary (1)
- p+p collisions (1)
- p47phox (1)
- pSMAD2 (1)
- patterns of progression (1)
- pediatric cancer (1)
- pediatric intensive care (1)
- pembrolizumab (1)
- perception (1)
- perceptual closure (1)
- perceptual organization (1)
- pericytes (1)
- periodontal probing, (1)
- perioperative ischemia (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peri‐implant probing (1)
- pertuzumab (1)
- phase IV (1)
- phenotype (1)
- phenotypic screening (1)
- phosphorus (1)
- phylogenetic community distance (1)
- phylogeny (1)
- phytometer (1)
- pivalate (1)
- pivoloyl (1)
- plant productivity (1)
- platelet lysate (1)
- platform switching (1)
- pleomorphic xanthoastrocytoma (1)
- point shear wave elastography (1)
- pole concept of goiter growth (1)
- polyacetylenes (1)
- polyines (1)
- polymorphism (1)
- polyynes (1)
- portal hypertension (1)
- post-transplantation lymphoproliferative disease (1)
- posterior horn (1)
- posteroinferior horn (1)
- precision weighting (1)
- precursor residence time (1)
- predictive biomarker (1)
- predictive biomarkers (1)
- predictive coding (1)
- pressure cycling technology (1)
- primary active transporters (1)
- primary brain tumors (1)
- primary immunodeficiency (PID) (1)
- prognosis (1)
- prophylaxis (1)
- proprotein convertase subtilisin/kexin type 9 inhibition (1)
- prosocial behavior (1)
- protein kinase (1)
- proteome (1)
- pulmonary embolism (1)
- pulsed-field (1)
- quark gluon plasma (1)
- radiotherapy (1)
- randomized (1)
- recurrence pattern (1)
- red blood cells (1)
- reference damage (1)
- registry for primary immunodeficiency (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- renin-angiotensin system (1)
- repetition suppression (RS) (1)
- reproducibility (1)
- resource limitation (1)
- respiratory infections (1)
- retinoid X receptor (1)
- rhabdomyosarcoma (1)
- rhinovirus (1)
- rigor (1)
- risk factor progression (1)
- risk factors (1)
- risk of malignancy (1)
- s-process (1)
- sEH (1)
- scanning laser Doppler vibrometry (1)
- second-line (1)
- second-line immunotherapy (1)
- seizures (1)
- sequence alignment (1)
- sex (1)
- signal processing (1)
- simulation (1)
- simulation training (1)
- single nucleotide polymorphism (1)
- single subject classification (1)
- small molecule inhibitor (1)
- small molecules (1)
- social exclusion (1)
- social psychiatry (1)
- soft tissue sarcoma (1)
- solar physics (1)
- spectra (1)
- stability (1)
- stage II/III colorectal cancer (1)
- stakeholder (1)
- standardization (1)
- stearic acid (1)
- stereotactic radiosurgery (1)
- structural biology (1)
- structural health monitoring (1)
- subgrouping (1)
- surgery (1)
- synaesthesia (1)
- synchronization (1)
- synchrony (1)
- taller-than-wide (1)
- targeted axillary dissection (1)
- temozolomide (1)
- temporal classification (1)
- testis (1)
- tetracycline (1)
- theory of mind (1)
- therapeutic anticoagulation (1)
- therapy (1)
- therapy response (1)
- threats (1)
- thrombolysis (1)
- thrombolysis (tPA) (1)
- training (1)
- transfusion (1)
- transient elastography (1)
- trastuzumab (1)
- trauma (1)
- treatment resistance (1)
- tropical forests (1)
- tumor (1)
- tumor metabolism (1)
- tumor necrosis factor receptor superfamily member 9 (1)
- tumor-infiltrating lymphocytes (1)
- uncertainty (1)
- understudied kinase (1)
- uveal melanoma (1)
- valuation (1)
- vascular endothelial growth factor (1)
- vascular endothelial growth factor receptor (1)
- ventriculoperitoneal shunt (1)
- vessel-associated mural cells (1)
- visual priming (1)
- white and brown dwarfs (1)
- women (1)
- Υ suppression (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1214)
- Frankfurt Institute for Advanced Studies (FIAS) (1080)
- Informatik (925)
- Medizin (225)
- Geowissenschaften (16)
- Biowissenschaften (13)
- Biochemie und Chemie (11)
- Senckenbergische Naturforschende Gesellschaft (8)
- Institut für Ökologie, Evolution und Diversität (6)
- Biochemie, Chemie und Pharmazie (5)
Brain metastases are a common finding upon initial diagnosis of otherwise locally limited non-small cell lung cancer. We present a retrospective case series describing three cases of patients with symptomatic, synchronous brain metastases and resectable lung tumors. The patients received local ablative treatment of the brain metastases followed by neoadjuvant immunochemotherapy with pemetrexed, cisplatin, and pembrolizumab. Afterwards, resection of the pulmonary lesion with curative intent was performed. One patient showed progressive disease 12 months after initial diagnosis, and passed away 31 months after initial diagnosis. Two of the patients are still alive and maintain a good quality of life with a progression-free survival and overall survival of 28 and 35 months, respectively, illustrating the potential of novel combinatorial treatment approaches.
Epithelial-to-mesenchymal transition (EMT) is supposed to be responsible for increased invasion and metastases in epithelial cancer cells. The activation of EMT genes has further been proposed to be important in the process of malignant transformation of primary CNS tumors. Since the cellular source and clinical impact of EMT factors in primary CNS tumors still remain unclear, we aimed at deciphering their distribution in vivo and clinico-pathological relevance in human gliomas.
We investigated 350 glioma patients for the expression of the key EMT factors SLUG and TWIST by immunohistochemistry and immunofluorescence related to morpho-genetic alterations such as EGFR-amplification, IDH-1 (R132H) mutation and 1p/19q LOH. Furthermore, transcriptional cluster and survival analyses were performed.
Our data illustrate that SLUG and TWIST are overexpressed in gliomas showing vascular proliferation such as pilocytic astrocytomas and glioblastomas. EMT factors are exclusively expressed by non-neoplastic pericytes/vessel-associated mural cells (VAMCs). They are not associated with patient survival but correlate with pericytic/VAMC genes in glioblastoma cluster analysis.
In summary, the upregulation of EMT genes in pilocytic astrocytomas and glioblastomas reflects the level of activation of pericytes/VAMCs in newly formed blood vessels. Our results underscore that the negative prognostic potential of the EMT signature in the group of diffuse gliomas of WHO grade II-IV does most likely not derive from glioma cells but rather reflects the degree of proliferating mural cells thereby constituting a potential target for future alternative treatment approaches.
Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomustine therapy, baseline tumor tissue was evaluated to identify markers associated with tumor stage (e.g., histopathology, Ki67, glial fibrillary acidic protein) and TGF-β-related signaling (e.g., pSMAD2). Other pharmacodynamic assessments included chemokine, cytokine, and T cell subsets alterations. 158 patients were randomized to galunisertib plus lomustine (n = 79), galunisertib (n = 39) and placebo+lomustine (n = 40). In 127 of these patients, tissue was adequate for central pathology review and biomarker work. Isocitrate dehydrogenase (IDH1) negative glioblastoma patients with baseline pSMAD2+ in cytoplasm had median overall survival (OS) 9.5 months vs. 6.9 months for patients with no tumor pSMAD2 expression (p = 0.4574). Eight patients were IDH1 R132H+ and had a median OS of 10.4 months compared to 6.9 months for patients with negative IDH1 R132H (p = 0.5452). IDH1 status was associated with numerically higher plasma macrophage-derived chemokine (MDC/CCL22), higher whole blood FOXP3, and reduced tumor CD3+ T cell counts. Compared to the baseline, treatment with galunisertib monotherapy preserved CD4+ T cell counts, eosinophils, lymphocytes, and the CD4/CD8 ratio. The T-regulatory cell compartment was associated with better OS with MDC/CCL22 as a prominent prognostic marker.
The Gleason grading system remains the most powerful prognostic predictor for patients with prostate cancer since the 1960s. Its application requires highly-trained pathologists, is tedious and yet suffers from limited inter-pathologist reproducibility, especially for the intermediate Gleason score 7. Automated annotation procedures constitute a viable solution to remedy these limitations. In this study, we present a deep learning approach for automated Gleason grading of prostate cancer tissue microarrays with Hematoxylin and Eosin (H&E) staining. Our system was trained using detailed Gleason annotations on a discovery cohort of 641 patients and was then evaluated on an independent test cohort of 245 patients annotated by two pathologists. On the test cohort, the inter-annotator agreements between the model and each pathologist, quantified via Cohen’s quadratic kappa statistic, were 0.75 and 0.71 respectively, comparable with the inter-pathologist agreement (kappa = 0.71). Furthermore, the model’s Gleason score assignments achieved pathology expert-level stratification of patients into prognostically distinct groups, on the basis of disease-specific survival data available for the test cohort. Overall, our study shows promising results regarding the applicability of deep learning-based solutions towards more objective and reproducible prostate cancer grading, especially for cases with heterogeneous Gleason patterns.
The human immunodeficiency virus (HIV) protease inhibitor saquinavir shows anticancer activity. Although its nitric oxide-modified derivative saquinavir-NO (saq-NO) was less toxic to normal cells, it exerted stronger inhibition of B16 melanoma growth in syngeneic C57BL/6 mice than saquinavir did. Saq-NO has been shown to block proliferation, upregulate p53 expression, and promote differentiation of C6 glioma and B16 cells. The anticancer activity of substances is frequently hampered by cancer cell chemoresistance mechanisms. Therefore, we here investigated the roles of p53 and the ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1) in cancer cell sensitivity to saq-NO to get more information about the potential of saq-NO as anticancer drug. Saq-NO exerted anticancer effects in lower concentrations than saquinavir in a panel of human cancer cell lines. Neither p53 mutation or depletion nor expression of P-gp, MRP1, or BCRP1 affected anticancer activity of saq-NO or saquinavir. Moreover, saq-NO sensitized P-gp-, MRP1-, or BCRP1-expressing cancer cells to chemotherapy. Saq-NO induced enhanced sensitization of P-gp- or MRP1-expressing cancer cells to chemotherapy compared with saquinavir, whereas both substances similarly sensitized BCRP1-expressing cells. Washout kinetics and ABC transporter ATPase activities demonstrated that saq-NO is a substrate of P-gp as well as of MRP1. These data support the further investigation of saq-NO as an anticancer drug, especially in multidrug-resistant tumors.
Individual differences in perception are widespread. Considering inter-individual variability, synesthetes experience stable additional sensations; schizophrenia patients suffer perceptual deficits in, eg, perceptual organization (alongside hallucinations and delusions). Is there a unifying principle explaining inter-individual variability in perception? There is good reason to believe perceptual experience results from inferential processes whereby sensory evidence is weighted by prior knowledge about the world. Perceptual variability may result from different precision weighting of sensory evidence and prior knowledge. We tested this hypothesis by comparing visibility thresholds in a perceptual hysteresis task across medicated schizophrenia patients (N = 20), synesthetes (N = 20), and controls (N = 26). Participants rated the subjective visibility of stimuli embedded in noise while we parametrically manipulated the availability of sensory evidence. Additionally, precise long-term priors in synesthetes were leveraged by presenting either synesthesia-inducing or neutral stimuli. Schizophrenia patients showed increased visibility thresholds, consistent with overreliance on sensory evidence. In contrast, synesthetes exhibited lowered thresholds exclusively for synesthesia-inducing stimuli suggesting high-precision long-term priors. Additionally, in both synesthetes and schizophrenia patients explicit, short-term priors—introduced during the hysteresis experiment—lowered thresholds but did not normalize perception. Our results imply that perceptual variability might result from differences in the precision afforded to prior beliefs and sensory evidence, respectively.
Higher grade meningiomas tend to recur. We aimed to evaluate protein levels of vascular endothelial growth factor (VEGF)-A with the VEGF-receptors 1-3 and the co-receptors Neuropilin (NRP)-1 and -2 in WHO grade II and III meningiomas to elucidate the rationale for targeted treatments. We investigated 232 specimens of 147 patients suffering from cranial meningioma, including recurrent tumors. Immunohistochemistry for VEGF-A, VEGFR-1-3, and NRP-1/-2 was performed on tissue micro arrays. We applied a semiquantitative score (staining intensity x frequency). VEGF-A, VEGFR-1-3, and NRP-1 were heterogeneously expressed. NRP-2 was mainly absent. We demonstrated a significant increase of VEGF-A levels on tumor cells in WHO grade III meningiomas (p = 0.0098). We found a positive correlation between expression levels of VEGF-A and VEGFR-1 on tumor cells and vessels (p < 0.0001). In addition, there was a positive correlation of VEGF-A and VEGFR-3 expression on tumor vessels (p = 0.0034). VEGFR-2 expression was positively associated with progression-free survival (p = 0.0340). VEGF-A on tumor cells was negatively correlated with overall survival (p = 0.0084). The VEGF-A-driven system of tumor angiogenesis might still present a suitable target for adjuvant therapy in malignant meningioma disease. However, its role in malignant tumor progression may not be as crucial as expected. The value of comprehensive testing of the ligand and all receptors prior to administration of anti-angiogenic therapy needs to be evaluated in clinical trials.
Objective: To compare discomfort/pain following periodontal probing around teeth and peri‐implant probing around implants with or without platform switching.
Methods: Two dentists recruited and examined 65 patients, each of them exhibiting a dental implant with a contralateral tooth. Only two types of implants were included: one with and one without platform switching. Periodontal and peri‐implant probing depths (PPD) and probing attachment level (PAL) were assessed. Whether implant or tooth was measured first was randomly assigned. Immediately after probing, patients scored discomfort/pain using a visual analogue scale (VAS). The emergence profiles of implant crowns were assessed as angles between interproximal surfaces on radiographs.
Results: Sixty‐five patients (age 69; 63/76 years [median; lower/upper quartile]; 38 females, 11 smokers) were examined. With the exception of mean PPD and PAL (p < .05) clinical parameters (PPD, PAL, bleeding on probing, suppuration) were well balanced between implants and teeth. Peri‐implant probing (VAS: 10; 0.75/16.25) caused significantly (p < .001) more discomfort/pain than periodontal probing (4; 0/10). Logistic regression analysis identified a larger difference between discomfort/pain for peri‐implant and periodontal probing in the maxilla than the mandible (p = .003). Comparing discomfort/pain between implants maxilla (p = .006) and emergence profile (p = .015) were associated with discomfort/pain. Type of implant (with/without platform switching) had no significant effect on discomfort/pain.
Conclusions: Peri‐implant probing caused significantly more discomfort/pain than periodontal probing. Implant design with/without platform switching failed to have a significant effect on discomfort/pain.
Background
Cytochrome-P450 (CYP450) epoxygenases metabolise arachidonic acid (AA) into four different biologically active epoxyeicosatrienoic acid (EET) regioisomers. Three of the EETs (i.e., 8,9-, 11,12- and 14,15-EET) are rapidly hydrolysed by the enzyme soluble epoxide hydrolase (sEH). Here, we investigated the role of sEH in nociceptive processing during peripheral inflammation.
Results
In dorsal root ganglia (DRG), we found that sEH is expressed in medium and large diameter neurofilament 200-positive neurons. Isolated DRG-neurons from sEH-/- mice showed higher EET and lower DHET levels. Upon AA stimulation, the largest changes in EET levels occurred in culture media, indicating both that cell associated EET concentrations quickly reach saturation and EET-hydrolyzing activity mostly effects extracellular EET signaling. In vivo, DRGs from sEH-deficient mice exhibited elevated 8,9-, 11,12- and 14,15-EET-levels. Interestingly, EET levels did not increase at the site of zymosan-induced inflammation. Cellular imaging experiments revealed direct calcium flux responses to 8,9-EET in a subpopulation of nociceptors. In addition, 8,9-EET sensitized AITC-induced calcium increases in DRG neurons and AITC-induced calcitonin gene related peptide (CGRP) release from sciatic nerve axons, indicating that 8,9-EET sensitizes TRPA1-expressing neurons, which are known to contribute to mechanical hyperalgesia. Supporting this, sEH-/- mice showed increased nociceptive responses to mechanical stimulation during zymosan-induced inflammation and 8,9-EET injection reduced mechanical thresholds in naive mice.
Conclusion
Our results show that the sEH can regulate mechanical hyperalgesia during inflammation by inactivating 8,9-EET, which sensitizes TRPA1-expressing nociceptors. Therefore we suggest that influencing the CYP450 pathway, which is actually highly considered to treat cardiovascular diseases, may cause pain side effects.
The dismal prognosis of pediatric and young adult patients with high-risk rhabdomyosarcoma (RMS) underscores the need for novel treatment options for this patient group. In previous studies, the tumor-associated surface antigen ERBB2 (HER2/neu) was identified as targetable in high-risk RMS. As a proof of concept, in this study, a novel treatment approach against RMS tumors using a genetically modified natural killer (NK)-92 cell line (NK-92/5.28.z) as an off-the-shelf ERBB2-chimeric antigen receptor (CAR)-engineered cell product was preclinically explored. In cytotoxicity assays, NK-92/5.28.z cells specifically recognized and efficiently eliminated RMS cell suspensions, tumor cell monolayers, and 3D tumor spheroids via the ERBB2-CAR even at effector-to-target ratios as low as 1:1. In contrast to unmodified parental NK-92 cells, which failed to lyse RMS cells, NK-92/5.28.z cells proliferated and became further activated through contact with ERBB2-positive tumor cells. Furthermore, high amounts of effector molecules, such as proinflammatory and antitumoral cytokines, were found in cocultures of NK-92/5.28.z cells with tumor cells. Taken together, our data suggest the enormous potential of this approach for improving the immunotherapy of treatment-resistant tumors, revealing the dual role of NK-92/5.28.z cells as CAR-targeted killers and modulators of endogenous adaptive immunity even in the inhibitory tumor microenvironment of high-risk RMS.
High-risk rhabdomyosarcoma (RMS) occurring in childhood to young adulthood is associated with a poor prognosis; especially children above the age of 10 with advanced stage alveolar RMS still succumb to the disease within a median of 2 years. The advent of chimeric antigen receptor (CAR)-engineered T cells marked significant progress in the treatment of refractory B cell malignancies, but experience for solid tumors has proven challenging. We speculate that this is at least in part due to the poor quality of the patient's own T cells and therefore propose using CAR-modified cytokine-induced killer (CIK) cells as effector cells. CIK cells are a heterogeneous population of polyclonal T cells that acquire phenotypic and cytotoxic properties of natural killer (NK) cells through the cultivation process, becoming so-called T-NK cells. CIK cells can be genetically modified to express CARs. They are minimally alloreactive and can therefore be acquired from haploidentical first-degree relatives. Here, we explored the potential of ERBB2-CAR-modified random-donor CIK cells as a treatment for RMS in xenotolerant mice bearing disseminated high-risk RMS tumors. In otherwise untreated mice, RMS tumors engrafted 13–35 days after intravenous tumor cell injection, as shown by in vivo bioluminescence imaging, immunohistochemistry, and polymerase chain reaction for human gDNA, and mice died shortly thereafter (median/range: 62/56–66 days, n = 5). Wild-type (WT) CIK cells given at an early stage delayed and eliminated RMS engraftment in 4 of 6 (67%) mice, while ERBB2-CAR CIK cells inhibited initial tumor load in 8 of 8 (100%) mice. WT CIK cells were detectable but not as active as CAR CIK cells at distant tumor sites. CIK cell therapies during advanced RMS delayed but did not inhibit tumor progression compared to untreated controls. ERBB2-CAR CIK cell therapy also supported innate immunity as evidenced by selective accumulation of NK and T-NK cell subpopulations in disseminated RMS tumors, which was not observed for WT CIK cells. Our data underscore the power of heterogenous immune cell populations (T, NK, and T-NK cells) to control solid tumors, which can be further enhanced with CARs, suggesting ERBB2-CAR CIK cells as a potential treatment for high-risk RMS.
We report a measurement of the observed cross sections of e+ e− → J/ψX based on 3.21 fb − 1 of data accumulated at energies from 3.645 to 3.891 GeV with the BESIII detector operated at the BEPCII collider. In analysis of the cross sections, we measured the decay branching fractions of B(ψ(3686) → J/ψX) = (64.4 ± 0.6 ± 1.6)% and B(ψ(3770) → J/ψX) = (0.5 ± 0.2 ± 0.1)% for the first time. The energy-dependent line shape of these cross sections cannot be well described by two Breit-Wigner (BW) amplitudes of the expected decays ψ (3686) → J/ψX and ψ(3770) → J/ψX. Instead, it can be better described with one more BW amplitude of the decay R(3760)→ J/ψX. Under this assumption, we extracted the R (3760) mass M R (3760 ) = 3766.2 ± 3.8 ± 0.4 MeV/c2, total width Γ tot R ( 3760 ) = 22.2 ± 5.9 ± 1.4 MeV, and product of leptonic width and decay branching fraction
ΓeeR(3760) B[R(3760) → J/ψX] = (79.4 ± 85.5 ± 11.7) eV. The significance of the R(3760) is 5.3σ. The first uncertainties of these measured quantities are from fits to the cross sections and second systematic.
In ischemic vascular diseases, leukocyte recruitment and polarization are crucial for revascularization and tissue repair. We investigated the role of vasodilator-stimulated phosphoprotein (VASP) in vascular repair. After hindlimb ischemia induction, blood flow recovery, angiogenesis, arteriogenesis, and leukocyte infiltration into ischemic muscles in VASP−/− mice were accelerated. VASP deficiency also elevated the polarization of the macrophages through increased signal transducer and activator of transcription (STAT) signaling, which augmented the release of chemokines, cytokines, and growth factors to promote leukocyte recruitment and vascular repair. Importantly, VASP deletion in bone marrow–derived cells was sufficient to mimic the increased blood flow recovery of global VASP−/− mice. In chemotaxis experiments, VASP−/− neutrophils/monocytes were significantly more responsive to M1-related chemokines than wild-type controls. Mechanistically, VASP formed complexes with the chemokine receptor CCR2 and β-arrestin-2, and CCR2 receptor internalization was significantly reduced in VASP−/− leukocytes. Our data indicate that VASP is a major regulator of leukocyte recruitment and polarization in postischemic revascularization and support a novel role of VASP in chemokine receptor trafficking.
Aim: NADPH oxidases are important sources of reactive oxygen species (ROS). Several Nox homologues are present together in the vascular system but whether they exhibit crosstalk at the activity level is unknown. To address this, vessel function of knockout mice for the cytosolic Nox organizer proteins p47phox, NoxO1 and a p47phox-NoxO1-double knockout were studied under normal condition and during streptozotocin-induced diabetes.
Results: In the mouse aorta, mRNA expression for NoxO1 was predominant in smooth muscle and endothelial cells, whereas p47phox was markedly expressed in adventitial cells comprising leukocytes and tissue resident macrophages. Knockout of either NoxO1 or p47phox resulted in lower basal blood pressure. Deletion of any of the two subunits also prevented diabetes-induced vascular dysfunction. mRNA expression analysis by MACE (Massive Analysis of cDNA ends) identified substantial gene expression differences between the mouse lines and in response to diabetes. Deletion of p47phox induced inflammatory activation with increased markers of myeloid cells and cytokine and chemokine induction. In contrast, deletion of NoxO1 resulted in an attenuated interferon gamma signature and reduced expression of genes related to antigen presentation. This aspect was also reflected by a reduced number of circulating lymphocytes in NoxO1-/- mice.
Innovation and conclusion: ROS production stimulated by NoxO1 and p47phox limit endothelium-dependent relaxation and maintain blood pressure in mice. However, NoxO1 and p47phox cannot substitute each other despite their similar effect on vascular function. Deletion of NoxO1 induced an anti-inflammatory phenotype, whereas p47phox deletion rather elicited a hyper-inflammatory response.
Background: The evaluation of local mental health care remains difficult. For this reason systematic development of appropriate services is barely possible.
Methods: We examined involuntary hospitalization in the city of Frankfurt/Main with regard to diagnoses, socio-demographic data, complementary psychosocial outpatient care, and circumstances of hospitalization. There are four psychiatric clinics, each serving a catchment area of more than 165.000 inhabitants. These clinics are responsible for all psychiatric in-patient treatments regardless of the admission modus. During a one year period, 677 patients were involuntarily hospitalized. Statistical analyses were performed subsequent to pooling the data.
Results: During a period of one year, 103 out of 100.000 inhabitants of Frankfurt/Main were admitted involuntarily. The rate of involuntary admissions related to all admissions was 10.98 percent. Any complementary psychosocial care was missing in more than 70 percent of patients admitted involuntarily. Only about 10 percent of patients were examined by a physician before reaching the hospital and in disappointing 1.3 percent the municipal mental health service had been consulted prior to involuntarily admission.
Conclusion: Our results show that a systematic improvement of precautionary complementary psychosocial care for risk patients is needed as well as the obligation of psychiatric emergency consultation before involuntary hospitalization.
Subvisible cirrus clouds (SVCs) may contribute to dehydration close to the tropical tropopause. The higher and colder SVCs and the larger their ice crystals, the more likely they represent the last efficient point of contact of the gas phase with the ice phase and, hence, the last dehydrating step, before the air enters the stratosphere. The first simultaneous in situ and remote sensing measurements of SVCs were taken during the APE-THESEO campaign in the western Indian ocean in February/March 1999. The observed clouds, termed Ultrathin Tropical Tropopause Clouds (UTTCs), belong to the geometrically and optically thinnest large-scale clouds in the Earth´s atmosphere. Individual UTTCs may exist for many hours as an only 200--300 m thick cloud layer just a few hundred meters below the tropical cold point tropopause, covering up to 105 km2. With temperatures as low as 181 K these clouds are prime representatives for defining the water mixing ratio of air entering the lower stratosphere.
Mechanisms by which subvisible cirrus clouds (SVCs) might contribute to dehydration close to the tropical tropopause are not well understood. Recently Ultrathin Tropical Tropopause Clouds (UTTCs) with optical depths around 10-4 have been detected in the western Indian ocean. These clouds cover thousands of square kilometers as 200-300 m thick distinct and homogeneous layer just below the tropical tropopause. In their condensed phase UTTCs contain only 1-5% of the total water, and essentially no nitric acid. A new cloud stabilization mechanism is required to explain this small fraction of the condensed water content in the clouds and their small vertical thickness. This work suggests a mechanism, which forces the particles into a thin layer, based on upwelling of the air of some mm/s to balance the ice particles, supersaturation with respect to ice above and subsaturation below the UTTC. In situ measurements suggest that these requirements are fulfilled. The basic physical properties of this mechanism are explored by means of a single particle model. Comprehensive 1-D cloud simulations demonstrate this stabilization mechanism to be robust against rapid temperature fluctuations of +/- 0.5 K. However, rapid warming (Delta T > 2 K) leads to evaporation of the UTTC, while rapid cooling (Delta T < -2 K) leads to destabilization of the particles with the potential for significant dehydration below the cloud
We have used the SLIMCAT 3-D off-line chemical transport model (CTM) to quantify the Arctic chemical ozone loss in the year 2002/2003 and compare it with similar calculations for the winters 1999/2000 and 2003/2004. Recent changes to the CTM have improved the model's ability to reproduce polar chemical and dynamical processes. The updated CTM uses σ-θ as a vertical coordinate which allows it to extend down to the surface. The CTM has a detailed stratospheric chemistry scheme and now includes a simple NAT-based denitrification scheme in the stratosphere.
In the model runs presented here the model was forced by ECMWF ERA40 and operational analyses. The model used 24 levels extending from the surface to ~55km and a horizontal resolution of either 7.5° x 7.5° or 2.8° x 2.8°. Two different radiation schemes, MIDRAD and the CCM scheme, were used to diagnose the vertical motion in the stratosphere. Based on tracer observations from balloons and aircraft, the more sophisticated CCM scheme gives a better representation of the vertical transport in this model which includes the troposphere. The higher resolution model generally produces larger chemical O3 depletion, which agrees better with observations.
The CTM results show that very early chemical ozone loss occurred in December 2002 due to extremely low temperatures and early chlorine activation in the lower stratosphere. Thus, chemical loss in this winter started earlier than in the other two winters studied here. In 2002/2003 the local polar ozone loss in the lower stratosphere was ~40% before the stratospheric final warming. Larger ozone loss occurred in the cold year 1999/2000 which had a persistently cold and stable vortex during most of the winter. For this winter the current model, at a resolution of 2.8° x 2.8°, can reproduce the observed loss of over 70% locally. In the warm and more disturbed winter 2003/2004 the chemical O3 loss was generally much smaller, except above 620K where large losses occurred due to a period of very low minimum temperatures at these altitudes.
Background: Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microenvironment, we investigated whether the MI concentration in the tumor changes during therapy.
Methods: We used 1H-magnetic resonance spectroscopy to measure the MI concentrations in the tumor and contralateral control tissue of 39 prospectively recruited patients with recurrent glioblastomas before and 8–12 weeks after starting therapy. 30 patients received Bevacizumab and 9 patients were treated with CCNU/VM26 as control. We performed a survival analysis to evaluate MI as a predictive biomarker for Bevacizumab therapy.
Results: MI concentrations increased significantly during Bevacizumab therapy in tumor (p < .001) and control tissue (p = .001), but not during CCNU/VM26 treatment. For the Bevacizumab cohort, higher MI concentrations in the control tissue at baseline (p = .021) and higher differences between control and tumor tissue (delta MI, p = .011) were associated with longer survival. A Kaplan-Meier analysis showed a median OS of 164 days for patients with a deltaMI < 1,817 mmol/l and 275 days for patients with a deltaMI > 1,817 mmol/l. No differences were observed for the relative changes or the post treatment concentrations. Additionally calculated creatine concentrations showed no differences in between subgroups or between pre and post treatment measurements.
Conclusion: Our data suggest that recurrent glioblastoma shows a strong metabolic reaction to Bevacizumab. Further, our results support the hypothesis that MI might be a marker for early tumor cell invasion. Pre-therapeutic MI concentrations are predictive of overall survival in patients with recurrent glioblastoma treated with Bevacizumab.
Ventriculoperitoneal shunts equipped with a reservoir and a valve to manually switch off the shunt function can be used for intraventricular injections of therapeutics in patients suffering from a communicating hydrocephalus caused by leptomeningeal metastases. These shunt devices avoid the risk of injecting therapeutics through the distal leg of the shunt system into the intraperitoneal space, which may cause toxicity. Furthermore, regular intraventricular injections of chemotherapeutics help to maintain sufficient concentrations in the ventricular space. Therefore, ventriculoperitoneal shunts equipped with an on-off valve are a useful tool to reliably inject chemotherapeutics into the ventricles. In order to systematically assess feasibility, safety, and efficacy of this procedure, we performed a retrospective analysis of all patients with leptomeningeal metastases who had received a shunt system at our institution. In total, six adult patients had a ventriculoperitoneal shunt equipped with an on-off valve implanted. Out of these six patients, two patients subsequently received intraventricular injections of chemotherapeutics. The configuration of the valve setting and the intraventricular injections were easily feasible in the setting of a neuro-oncology department. The complication of a shunt leakage occurred in one patient following the first intraventricular injection. No extra-central nervous system (CNS) toxicities were observed. In summary, ventriculoperitoneal shunts with on-off valves are useful tools for reliable intraventricular administration of therapeutics.
Simple Summary: Targeted therapies are of growing interest to physicians in cancer treatment. These drugs target specific genes and proteins involved in the growth and survival of cancer cells. Brain tumor therapy is complicated by the fact that not all drugs can penetrate the blood brain barrier and reach their target. We explored the non-invasive method, Magnetic Resonance Spectroscopy, for monitoring drug penetration and its effects in live animals bearing brain tumors. We were able to show the presence of the investigated drug in mouse brains and its on-target activity.
Abstract: Background: BAY1436032 is a fluorine-containing inhibitor of the R132X-mutant isocitrate dehydrogenase (mIDH1). It inhibits the mIDH1-mediated production of 2-hydroxyglutarate (2-HG) in glioma cells. We investigated brain penetration of BAY1436032 and its effects using 1H/19F-Magnetic Resonance Spectroscopy (MRS). Methods: 19F-Nuclear Magnetic Resonance (NMR) Spectroscopy was conducted on serum samples from patients treated with BAY1436032 (NCT02746081 trial) in order to analyze 19F spectroscopic signal patterns and concentration-time dynamics of protein-bound inhibitor to facilitate their identification in vivo MRS experiments. Hereafter, 30 mice were implanted with three glioma cell lines (LNT-229, LNT-229 IDH1-R132H, GL261). Mice bearing the IDH-mutated glioma cells received 5 days of treatment with BAY1436032 between baseline and follow-up 1H/19F-MRS scan. All other animals underwent a single scan after BAY1436032 administration. Mouse brains were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). Results: Evaluation of 1H-MRS data showed a decrease in 2-HG/total creatinine (tCr) ratios from the baseline to post-treatment scans in the mIDH1 murine model. Whole brain concentration of BAY1436032, as determined by 19F-MRS, was similar to total brain tissue concentration determined by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS), with a signal loss due to protein binding. Intratumoral drug concentration, as determined by LC-MS/MS, was not statistically different in models with or without R132X-mutant IDH1 expression. Conclusions: Non-invasive monitoring of mIDH1 inhibition by BAY1436032 in mIDH1 gliomas is feasible.
Purpose: Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As molecularly stratified treatment data outside clinical trials are scarce, we conducted this retrospective study.
Methods: We identified 343 patients (1995–2015) with newly diagnosed WHO grade II/III gliomas and analyzed molecular markers, patient characteristics, symptoms, histology, treatment, time to treatment failure (TTF) and OS.
Results: IDH-status was available for all patients (259 mutant, 84 IDH1-R132H-non-mutant). Molecular subclassification was possible in 173 tumors, resulting in diagnosis of 80 astrocytomas and 93 oligodendrogliomas. WHO grading remained significant for OS in astrocytomas/IDH1-R132H-non-mutant gliomas (p < 0.01) but not for oligodendroglioma (p = 0.27). Chemotherapy (and temozolomide in particular) showed inferior OS compared to radiotherapy in astrocytomas (median 6.1/12.1 years; p = 0.03) and oligodendrogliomas (median 13.2/not reached (n.r.) years; p = 0.03). While radiochemotherapy improved TTF in oligodendroglioma (median radiochemotherapy n.r./chemotherapy 3.8/radiotherapy 7.3 years; p < 0.001/ = 0.06; OS data immature) the effect, mainly in combination with temozolomide, was weaker in astrocytomas (median radiochemotherapy 6.7/chemotherapy 2.3/radiotherapy 2.0 years; p < 0.001/ = 0.11) and did not translate to improved OS (median 8.4 years).
Conclusion: This is one of the largest retrospective, real-life datasets reporting treatment and outcome in low-grade gliomas incorporating molecular markers. Current histologic grading features remain prognostic in astrocytomas while being insignificant in oligodendroglioma with interfering treatment effects. Chemotherapy (temozolomide) was less effective than radiotherapy in both astrocytomas and oligodendrogliomas while radiochemotherapy showed the highest TTF in oligodendrogliomas.
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still more controversial. Therefore, we prepared a retrospective case series with 16 patients suffering from a multifocal glioblastoma treated with BEV. We compared these patients to a matched control cohort of 16 patients suffering from glioblastoma with a single lesion treated with BEV. The objective of this study was to evaluate whether the course of disease differs in glioblastoma patients with a multifocal disease pattern compared to those with a single lesion only. Patients were treated with BEV monotherapy or BEV in combination with irinotecan or lomustine (CCNU). Response rates and PFS were similar in both groups. There was a trend for an unfavorable OS in the patient group with multifocal glioblastoma, which was expected due to the generally worse prognosis of multifocal glioblastoma. We investigated whether BEV therapy affects the invasive growth pattern as measured by the appearance of new lesions on magnetic resonance imaging (MRI). Under BEV therapy, there was a trend for a lower frequency of new lesions both in multifocal and solitary glioblastoma. Based on these results, BEV therapy at relapse appears to be justified to no lesser extent in multifocal glioblastoma than in solitary glioblastoma.
Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern
(2017)
Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with gliomas showing a gliomatosis cerebri growth pattern is contentious. Due to the marked diffuse and infiltrative growth with less angiogenic tumor growth, it may appear questionable whether bevacizumab can have a therapeutic effect in those patients. However, the development of nodular, necrotic, and/or contrast-enhancing lesions in patients with a gliomatosis cerebri growth pattern is not uncommon and may indicate focal neo-angiogenesis. Therefore, control of growth of these lesions as well as control of edema and reduction of steroid use may be regarded as rationales for the use of bevacizumab in these patients. In this retrospective patient series, we report on 17 patients with primary brain tumors displaying a gliomatosis cerebri growth pattern (including seven glioblastomas, two anaplastic astrocytomas, one anaplastic oligodendroglioma, and seven diffuse astrocytomas). Patients have been treated with bevacizumab alone or in combination with lomustine or irinotecan. Seventeen matched patients treated with bevacizumab for gliomas with a classical growth pattern served as a control cohort. Response rate, progression-free survival, and overall survival were similar in both groups. Based on these results, anti-angiogenic therapy with bevacizumab should also be considered in patients suffering from gliomas with a mainly infiltrative phenotype.
When a visual stimulus is repeated, average neuronal responses typically decrease, yet they might maintain or even increase their impact through increased synchronization. Previous work has found that many repetitions of a grating lead to increasing gamma-band synchronization. Here, we show in awake macaque area V1 that both repetition-related reductions in firing rate and increases in gamma are specific to the repeated stimulus. These effects show some persistence on the timescale of minutes. Gamma increases are specific to the presented stimulus location. Further, repetition effects on gamma and on firing rates generalize to images of natural objects. These findings support the notion that gamma-band synchronization subserves the adaptive processing of repeated stimulus encounters.
When a visual stimulus is repeated, average neuronal responses typically decrease, yet they might maintain or even increase their impact through increased synchronization. Previous work has found that many repetitions of a grating lead to increasing gamma-band synchronization. Here we show in awake macaque area V1 that both, repetition-related reductions in firing rate and increases in gamma are specific to the repeated stimulus. These effects showed some persistence on the timescale of minutes. Further, gamma increases were specific to the presented stimulus location. Importantly, repetition effects on gamma and on firing rates generalized to natural images. These findings suggest that gamma-band synchronization subserves the adaptive processing of repeated stimulus encounters, both for generating efficient stimulus responses and possibly for memory formation.
Background: Transfusion of red blood cells (RBC) in patients undergoing major elective cranial surgery is associated with increased morbidity, mortality and prolonged hospital length of stay (LOS). This retrospective single center study aims to identify the impact of RBC transfusions on skull-base and non-skull-base meningioma patients including the identification of risk factors for RBC transfusion.
Methods: From October 2009 - October 2016 we retrospectively analyzed 423 primary meningioma patients undergoing surgery for primary meningioma resection our department.
Results: Of these 423 patients, 68 (16.1%) received RBC transfusion and 355 (83.9%) did not receive RBC units. Preoperative anaemia rate was significantly higher in transfused patients (17.7%) compared to patients without RBC transfusion (6.2%; p = 0.0015). In transfused patients, postoperative complications as well as hospital LOS was significantly higher (p < 00001) compared to non-transfused patients. After multivariate analyses, risk factors for RBC transfusion were preoperative American Society of Anesthesiologists (ASA) physical status score (p = 0.0247), tumor size (p = 0.0006), surgical time (p = 0.0018) and intraoperative blood loss (p < 0.001). Kaplan-Meier curves revealed significant influence on overall survival by preoperative anaemia, RBC transfusion, smoking, cardiovascular disease, preoperative KPS ≤ 60% and age (elderly ≥ 75 years).
Conclusion: We concluded that blood loss due to large tumors or localization near large vessels are the main triggers for RBC transfusion in meningioma patients paired with a potential preselection that masks the effect of preoperative anaemia in multivariate analysis. Further studies evaluating the impact of preoperative anaemia management for reduction of RBC transfusion are needed to improve clinical outcomes of meningioma patients.
Background: The extent of preoperative peritumoral edema in glioblastoma (GBM) has been negatively correlated with patient outcome. As several ongoing studies are investigating T-cell based immunotherapy in GBM, we conducted this study to assess whether peritumoral edema with potentially increased intracranial pressure, disrupted tissue homeostasis and reduced local blood flow has influence on immune infiltration and affects survival.
Methods: A volumetric analysis of preoperative imaging (gadolinium enhanced T1 weighted MRI sequences for tumor size and T2 weighted sequences for extent of edema (including the infiltrative zone, gliosis etc.) was conducted in 144 patients using the BrainlabÒ software. Immunohistochemical staining was analyzed for lymphocytic- (CD 3+) and myeloid (CD15+) tumor infiltration. A retrospective analysis of patient-, surgical-, and molecular characteristics was performed using medical records.
Results: The edema to tumor ratio was neither associated with progression-free nor overall survival (p=0.90, p=0.74). However, GBM patients displaying IDH-1 wildtype had significantly higher edema to tumor ratio than patients displaying an IDH-1 mutation (p=0.01). Immunohistopathological analysis did not show significant differences in lymphocytic or myeloid tumor infiltration (p=0.78, p=0.74) between these groups.
Conclusion: In our cohort, edema to tumor ratio had no significant correlation with immune infiltration and outcome. However, patients with an IDH-1wildtype GBM had a significantly higher edema to tumor ratio compared to their IDH-1 mutated peer group. Further studies are necessary to elucidate the underlying mechanisms.
In this report, we perform structure validation of recently reported RNA phosphorothioate (PT) modifications, a new set of epitranscriptome marks found in bacteria and eukaryotes including humans. By comparing synthetic PT-containing diribonucleotides with native species in RNA hydrolysates by high-resolution mass spectrometry (MS), metabolic stable isotope labeling, and PT-specific iodine-desulfurization, we disprove the existence of PTs in RNA from E. coli, S. cerevisiae, human cell lines, and mouse brain. Furthermore, we discuss how an MS artifact led to the initial misidentification of 2′-O-methylated diribonucleotides as RNA phosphorothioates. To aid structure validation of new nucleic acid modifications, we present a detailed guideline for MS analysis of RNA hydrolysates, emphasizing how the chosen RNA hydrolysis protocol can be a decisive factor in discovering and quantifying RNA modifications in biological samples.
Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study.
Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were prospectively stained for sorafenib targets and potential biomarkers. Serum samples (first two cycles) were measured for vascular endothelial growth factors (VEGFs), vascular endothelial growth factor receptor 2 (VEGFR-2) and stromal cell-derived factor 1 (SDF1)α by enzyme-linked immunosorbent assay (ELISA).
Results: Gemcitabine plus sorafenib was generally well tolerated. Four and three patients achieved partial responses in the sorafenib and placebo groups, respectively. There was no difference in the primary end-point, median progression-free survival (PFS) for gemcitabine plus sorafenib versus gemcitabine plus placebo (3.0 versus 4.9 months, P = 0.859), and no difference for median overall survival (OS) (8.4 versus 11.2 months, P = 0.775). Patients with liver metastasis after resection of primary BTC survived longer with sorafenib (P = 0.019) compared to placebo. Patients who developed hand-foot syndrome (HFS) showed longer PFS and OS than patients without HFS. Two sorafenib targets, VEGFR-2 and c-kit, were not expressed in BTC samples. VEGFR-3 and Hif1α were associated with lymph node metastases and T stage. Absence of PDGFRβ expression correlated with longer PFS.
Conclusion: The addition of sorafenib to gemcitabine did not demonstrate improved efficacy in advanced BTC patients. Biomarker subgroup analysis suggested that some patients might benefit from combined treatment.
A detailed analysis of the chemical constituents of a Caribbean specimen of Aiolochroia crassa was performed. Five brominated products (1 -5) were isolated and one of these was a new bromotyrosine metabolite. The structure of the new compound 1 has been established from spectral studies. Compounds 1 and 2, which are the major brominated metabolites and have not been previously identified in any Aiolochroia species, could be usefully employed as chemotaxonomic markers.
Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. BD shows substantial clinical and genetic overlap with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying this etiological overlap remain largely unknown. A recent SCZ genome wide association study (GWAS) by the Psychiatric Genomics Consortium identified 128 independent genome-wide significant single nucleotide polymorphisms (SNPs). The present study investigated whether these SCZ-associated SNPs also contribute to BD development through the performance of association testing in a large BD GWAS dataset (9747 patients, 14278 controls). After re-imputation and correction for sample overlap, 22 of 107 investigated SCZ SNPs showed nominal association with BD. The number of shared SCZ-BD SNPs was significantly higher than expected (p = 1.46x10-8). This provides further evidence that SCZ-associated loci contribute to the development of BD. Two SNPs remained significant after Bonferroni correction. The most strongly associated SNP was located near TRANK1, which is a reported genome-wide significant risk gene for BD. Pathway analyses for all shared SCZ-BD SNPs revealed 25 nominally enriched gene-sets, which showed partial overlap in terms of the underlying genes. The enriched gene-sets included calcium- and glutamate signaling, neuropathic pain signaling in dorsal horn neurons, and calmodulin binding. The present data provide further insights into shared risk loci and disease-associated pathways for BD and SCZ. This may suggest new research directions for the treatment and prevention of these two major psychiatric disorders.
A new technique developed for measuring nuclear reactions at low momentum transfer with stored beams in inverse kinematics was successfully used to study isoscalar giant resonances. The experiment was carried out at the experimental heavy-ion storage ring (ESR) at the GSI facility using a stored 58Ni beam at 100 MeV/u and an internal helium gas-jet target. In these measurements, inelastically scattered α-recoils at very forward center-of-mass angles (θcm ≤ 1.5°) were detected with a dedicated setup, including ultra-high vacuum compatible detectors. Experimental results indicate a dominant contribution of the isoscalar giant monopole resonance at this very forward angular range. It was found that the monopole contribution exhausts 79+12−11% of the energy-weighted sum rule (EWSR), which agrees with measurements performed in normal kinematics. This opens up the opportunity to investigate the giant resonances in a large domain of unstable and exotic nuclei in the near future. It is a fundamental milestone towards new nuclear reaction studies with stored ion beams.
Simple cells in primary visual cortex were famously found to respond to low-level image components such as edges. Sparse coding and independent component analysis (ICA) emerged as the standard computational models for simple cell coding because they linked their receptive fields to the statistics of visual stimuli. However, a salient feature of image statistics, occlusions of image components, is not considered by these models. Here we ask if occlusions have an effect on the predicted shapes of simple cell receptive fields. We use a comparative approach to answer this question and investigate two models for simple cells: a standard linear model and an occlusive model. For both models we simultaneously estimate optimal receptive fields, sparsity and stimulus noise. The two models are identical except for their component superposition assumption. We find the image encoding and receptive fields predicted by the models to differ significantly. While both models predict many Gabor-like fields, the occlusive model predicts a much sparser encoding and high percentages of ‘globular’ receptive fields. This relatively new center-surround type of simple cell response is observed since reverse correlation is used in experimental studies. While high percentages of ‘globular’ fields can be obtained using specific choices of sparsity and overcompleteness in linear sparse coding, no or only low proportions are reported in the vast majority of studies on linear models (including all ICA models). Likewise, for the here investigated linear model and optimal sparsity, only low proportions of ‘globular’ fields are observed. In comparison, the occlusive model robustly infers high proportions and can match the experimentally observed high proportions of ‘globular’ fields well. Our computational study, therefore, suggests that ‘globular’ fields may be evidence for an optimal encoding of visual occlusions in primary visual cortex.
The establishment and maintenance of protected areas(PAs) is viewed as a key action in delivering post-2020 biodiversity targets. PAs often need to meet a multitude of objectives, ranging from biodiversity protection to ecosystem service provision and climate change mitigation. As available land and conservation funding are limited, optimizing resources by selecting the most beneficial PAs is vital. Here we present a decision support tool that enables a flexible approach to PA selection on a global scale, allowing different conservation objectives to be weighted and prioritized according to user-specified preferences. We apply the tool across 1347 terrestrial PAs and highlight frequent trade-offs among different objectives, e.g., between biodiversity protection and ecosystem integrity. These results indicate that decision makers must usually decide among conflicting objectives. To assist this our decision support tool provides an explicitly value-based approach that can help resolve such conflicts by considering divergent societal and political demands and values.
Establishing and maintaining protected areas (PAs) is a key action in delivering post-2020 biodiversity targets. PAs often need to meet multiple objectives, ranging from biodiversity protection to ecosystem service provision and climate change mitigation, but available land and conservation funding is limited. Therefore, optimizing resources by selecting the most beneficial PAs is vital. Here, we advocate for a flexible and transparent approach to selecting PAs based on multiple objectives, and illustrate this with a decision support tool on a global scale. The tool allows weighting and prioritization of different conservation objectives according to user-specified preferences as well as real-time comparison of the outcome. Applying the tool across 1,346 terrestrial PAs, we demonstrate that decision makers frequently face trade-offs among conflicting objectives, e.g., between species protection and ecosystem integrity. Nevertheless, we show that transparent decision support tools can reveal synergies and trade-offs associated with PA selection, thereby helping to illuminate and resolve land-use conflicts embedded in divergent societal and political demands and values.
Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy
(2021)
Background and purpose: Progressive multifocal leukoencephalopathy (PML) constitutes a severe disease with increasing incidence, mostly in the context of immunosuppressive therapies. A detailed understanding of immune response in PML appears critical for the treatment strategy. The aim was a comprehensive immunoprofiling and radiological characterization of magnetic resonance imaging (MRI) defined PML variants.
Methods: All biopsy-confirmed PML patients (n = 15) treated in our department between January 2004 and July 2019 were retrospectively analysed. Data from MRI, histology as well as detailed clinical and outcome data were collected. The MRI-defined variants of classical (cPML) and inflammatory (iPML) PML were discriminated based on the intensity of gadolinium enhancement. In these PML variants, intensity and localization (perivascular vs. parenchymal) of inflammation in MRI and histology as well as the cellular composition by immunohistochemistry were assessed. The size of the demyelinating lesions was correlated with immune cell infiltration.
Results: Patients with MRI-defined iPML showed a stronger intensity of inflammation with an increased lymphocyte infiltration on histological level. Also, iPML was characterized by a predominantly perivascular inflammation. However, cPML patients also demonstrated certain inflammatory tissue alterations. Infiltration of CD163-positive microglia and macrophage (M/M) subtypes correlated with PML lesion size.
Conclusions: The non-invasive MRI-based discrimination of PML variants allows for an estimation of inflammatory tissue alterations, although exhibiting limitations in MRI-defined cPML. The association of a distinct phagocytic M/M subtype with the extent of demyelination might reflect disease progression.
Background: SNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the role of IFNL4 variants with IFNL3-(rs12979860) and IFNL3-(rs8099917) on response to pegylated (PEG)-IFN and Ribavirin (RBV) in patients with chronic hepatitis C GT2/3.
Methods: We recruited 1006 patients with chronic hepatitis C and GT2/3 in a large German registry. A treatment with PEG-IFN and Ribavirin was started by 959 patients. We performed genotyping of IFNL3 (rs12979860, n = 726; rs8099917, n = 687) and of IFNL4 (ss469415590; n = 631).
Results: Both preferable IFNL3 genotypes were associated with RVR (both p<0.0001) rather than with SVR (rs12979860: p = 0.251; rs8099917: p = 0.447). Only RVR was linked to SVR in univariate and multivariate analyzes (both p<0.001). Concordance of genotyping in patients with available serum samples and EDTA blood samples (n = 259) was more than 96% for both IFNL3 SNPs. IFNL3-(rs12979860) correlated with IFNL4: 99.2% of patients with IFNL3-(rs12979860)-CC were IFNL4-(ss469415590)-TT/TT. IFNL3-(rs12979860)-CT was linked with IFNL4-(ss469415590)-TT/ΔG (98.0%) and IFNL3-(rs12979860)-TT was associated with IFNL4-(ss469415590)-ΔG/ΔG (97.6%).
Conclusion: IFNL3 genotyping from serum was highly efficient and can be used as an alternative if EDTA whole blood is not available. In Caucasian GT2/3 patients genotyping for INFL4-(ss469415590) does not lead to additional information for the decision-making process. Importantly, IFNL3 SNPs were not associated with SVR but with RVR. Even in the era of new direct acting antiviral (DAA) therapies, IFNL3 testing may therefore still be considered for naïve GT2/3 patients to decide if dual Peg-IFN/RBV therapy is an option in resource limited regions.
Background and Aims: In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects. However, predictive factors associated with hepatic decompensation during antiviral therapy are poorly defined.
Methods: In a retrospective cohort study, 68 patients with HCV-associated liver cirrhosis (mean MELD score 9.18±2.72) were treated with peginterferon and ribavirin. Clinical events indicating hepatic decompensation (onset of ascites, hepatic encephalopathy, upper gastrointestinal bleeding, hospitalization) as well as laboratory data were recorded at baseline and during a follow up period of 72 weeks after initiation of antiviral therapy. To monitor long term sequelae of end stage liver disease an extended follow up for HCC development, transplantation and death was applied (240weeks, ±SD 136weeks).
Results: Eighteen patients (26.5%) achieved a sustained virologic response. During the observational period a hepatic decompensation was observed in 36.8%. Patients with hepatic decompensation had higher MELD scores (10.84 vs. 8.23, p<0.001) and higher mean bilirubin levels (26.74 vs. 14.63 µmol/l, p<0.001), as well as lower serum albumin levels (38.2 vs. 41.1 g/l, p = 0.015), mean platelets (102.64 vs. 138.95/nl, p = 0.014) and mean leukocytes (4.02 vs. 5.68/nl, p = 0.002) at baseline as compared to those without decompensation. In the multivariate analysis the MELD score remained independently associated with hepatic decompensation (OR 1.56, 1.18–2.07; p = 0.002). When the patients were grouped according to their baseline MELD scores, hepatic decompensation occurred in 22%, 59%, and 83% of patients with MELD scores of 6–9, 10–13, and >14, respectively. Baseline MELD score was significantly associated with the risk for transplantation/death (p<0.001).
Conclusions: Our data suggest that the baseline MELD score predicts the risk of hepatic decompensation during antiviral therapy and thus contributes to decision making when antiviral therapy is discussed in HCV patients with advanced liver cirrhosis.
The third dataset dedicated to the Open Guided Waves platform aims at carbon fiber composite plates with an additional omega stringer at constant temperature conditions. The two structures used in this work are representative for real aircraft components. Comprehensive measurements were recorded in order to study (I) the impact of the omega stringer on guided wave propagation, and (II) elliptical reference damages of different sizes located at three separate positions on the structure. Measurements were recorded for narrowband excitation (5-cycle toneburst with varying carrier frequencies) and broadband excitation (using chirp waveforms). The paper presents the results of a technical validation including numerical modelling, and enables further research, for example related to probability of detection (POD) analysis.
Ultrasonic guided waves have been used successfully in structural health monitoring systems to detect damage in isotropic and composite materials with simple and complex geometry. A limitation of current research is given by a lack of freely available benchmark measurements to comparatively evaluate existing methods. This article introduces the extendable online platform Open Guided Waves (http://www.open-guided-waves.de) where high-quality and well-documented datasets for guided wave-based inspections are provided. In this article, we describe quasi-isotropic carbon-fiber-reinforced polymer plates with embedded piezoelectric transducers as a first benchmark structure. Intentionally, this is a structure of medium complexity to enable many researchers to apply their methods. In a first step, ultrasound and X-ray measurements were acquired to verify pristine conditions. Next, mechanical testing was done to determine the stiffness tensor and sample density based on standard test procedures. Guided wave measurements were divided into two parts: first, acoustic wave fields were acquired for a broad range of frequencies by three-dimensional scanning laser Doppler vibrometry. Second, structural health monitoring measurements in the carbon-fiber-reinforced polymer plate were collected at constant temperature using a distributed transducer network and a surface-mounted reversible defect model. Initial results serving as validation are presented and discussed.
The retinoid X receptor (RXR) is a ligand-sensing transcription factor acting mainly as a universal heterodimer partner for other nuclear receptors. Despite presenting as a potential therapeutic target for cancer and neurodegeneration, adverse effects typically observed for RXR agonists, likely due to the lack of isoform selectivity, limit chemotherapeutic application of currently available RXR ligands. The three human RXR isoforms exhibit different expression patterns; however, they share high sequence similarity, presenting a major obstacle toward the development of subtype-selective ligands. Here, we report the discovery of the saturated fatty acid, palmitic acid, as an RXR ligand and disclose a uniform set of crystal structures of all three RXR isoforms in an active conformation induced by palmitic acid. A structural comparison revealed subtle differences among the RXR subtypes. We also observed an ability of palmitic acid as well as myristic acid and stearic acid to induce recruitment of steroid receptor co-activator 1 to the RXR ligand-binding domain with low micromolar potencies. With the high, millimolar endogenous concentrations of these highly abundant lipids, our results suggest their potential involvement in RXR signaling.
Ataxia telangiectasia (A-T) is a rare, progressive, multisystem disease that has a large number of complex and diverse manifestations which vary with age. Patients with A-T die prematurely with the leading causes of death being respiratory diseases and cancer. Respiratory manifestations include immune dysfunction leading to recurrent upper and lower respiratory infections; aspiration resulting from dysfunctional swallowing due to neurodegenerative deficits; inefficient cough; and interstitial lung disease/pulmonary fibrosis. Malnutrition is a significant comorbidity. The increased radiosensitivity and increased risk of cancer should be borne in mind when requesting radiological investigations. Aggressive proactive monitoring and treatment of these various aspects of lung disease under multidisciplinary expertise in the experience of national multidisciplinary clinics internationally forms the basis of this statement on the management of lung disease in A-T. Neurological management is outwith the scope of this document.
Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients
(2019)
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this retrospective study was to investigate REG penetration to cerebrospinal fluid (CSF), treatment efficacy, and effects on magnetic resonance imaging (MRI) in patients with recurrent high-grade gliomas.
(2) Methods: Patients were characterized by histology, adverse events, steroid treatment, overall survival (OS), and MRI growth pattern. REG and its two active metabolites were quantified by liquid chromatography/tandem mass spectrometry in patients’ serum and CSF.
(3) Results: 21 patients mainly with IDH-wildtype glioblastomas who had been treated with REG were retrospectively identified. Thirteen CFS samples collected from 3 patients of the cohort were available for pharmacokinetic testing. CSF levels of REG and its metabolites were significantly lower than in serum. Follow-up MRI was available in 19 patients and showed progressive disease (PD) in all but 2 patients. Two distinct MRI patterns were identified: 7 patients showed classic PD with progression of contrast enhancing lesions, whereas 11 patients showed a T2-dominant MRI pattern characterized by a marked reduction of contrast enhancement. Median OS was significantly better in patients with a T2-dominant growth pattern (10 vs. 27 weeks respectively, p = 0.003). Diffusion restrictions were observed in 13 patients.
(4) Conclusion: REG and its metabolites were detectable in CSF. A distinct MRI pattern that might be associated with an improved OS was observed in half of the patient cohort. Treatment response in the total cohort was poor.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.